We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
03 Mar 2021 - 05 Mar 2021
Virtual Venue
06 Mar 2021 - 10 Mar 2021
Virtual Venue

Cell-Free DNA Detects Heart Allograft Acute Rejection

By LabMedica International staff writers
Posted on 02 Feb 2021
Print article
Image: DNA fragments (yellow) derived from a transplanted heart alongside the patient’s own DNA (blue). A new blood test measures donor DNA fragments and detects acute heart transplant rejection earlier than current methods (Photo courtesy of Erina He, NIH Medical Arts)
Image: DNA fragments (yellow) derived from a transplanted heart alongside the patient’s own DNA (blue). A new blood test measures donor DNA fragments and detects acute heart transplant rejection earlier than current methods (Photo courtesy of Erina He, NIH Medical Arts)
After heart transplantation, Endomyocardial biopsy (EMBx) is used to monitor for acute rejection (AR). Unfortunately, EMBx is invasive and its conventional histologic interpretation has limitations.

About 2,000 heart transplants are performed each year in the USA, but not all are successful. Current tests used to detect heart transplant rejection rely on frequent and painful biopsies of heart tissue. Those biopsies run the risk of damaging the heart and are limited by their invasiveness and reliability.

A team of Medical Scientists led by those at The Johns Hopkins School of Medicine (Baltimore, MD, USA) collected blood samples from 171 people who had recently undergone a heart transplant at one of five centers in or near the District of Columbia, USA. The sampling included nearly 2,000 cell-free DNA measurements. The population was about 44% Black. The team monitored the patients for signs of acute rejection for nearly 18 months using both traditional heart tissue biopsy and the new blood test.

The test, called the donor-derived cell-free DNA (ddcfDNA) test, tracks DNA markers from the organ donor that appear in the blood of the transplant recipient. Because injured or dying cells from the donor organ release lots of donor DNA fragments into the bloodstream compared to normal cells, higher amounts of donor DNA indicate a higher risk for transplant rejection. The biomarkers can be detected using specialized laboratory equipment.

The scientists found the blood test performed better in their study than tissue biopsy, detecting higher amounts of rejection markers and earlier signs of rejection. It also detected more instances of other types of transplant injury that were missed by biopsy, including so-called antibody mediated rejection, one of the deadliest forms of rejection and the hardest to treat and diagnose. The new blood test may be able to detect rejection as early as 28 days after heart transplantation and at least three months before rejection is detectable using heart tissue biopsy.

Hannah A. Valantine, MD, the senior study author and a professor of cardiovascular medicine, said. “We showed in our initial assessment that this ‘liquid biopsy’ is highly sensitive for detecting acute rejection (AR), finding it weeks to months before current clinical tools. This could potentially save lives in the wake of a critical shortage of donor organs.”

The authors concluded that the percent donor-derived cell-free DNA (%ddcfDNA) detected acute rejection with a high area-under-the- receiver-operator characteristics curve (AUROC) and negative predictive value (NPV). Monitoring with ddcfDNA, demonstrated excellent performance characteristics for both acute cellular rejection (ACR) and antibody-mediated rejection (AMR) and led to earlier detection than the EMBx-based monitoring. This study supports the use of %ddcfDNA to monitor for AR in heart transplant patients and paves the way for a clinical utility study. The study was published on January 13, 2021 in the journal Circulation.

Related Links:
The Johns Hopkins School of Medicine

New
Gold Supplier
Cytocentrifuge
Cytopro Cytocentrifuge Series 2
New
Hematology Analyzer
DxH 560 AL
Influenza & COVID-19 Test
Influenza & COVID-19 Ag Combo Rapid Test Cassette (Swab)
Flu + SARS Antigen Test
Sofia 2 Flu + SARS Antigen FIA

Print article

Channels

Industry

view channel
Image: Sysmex CN-Series automated blood coagulation analyzer (Photo courtesy of Sysmex Corporation)

Siemens and Sysmex Extend Agreement to Provide One of the Largest Portfolios of Hemostasis Testing Systems and Reagents

Siemens Healthineers (Erlangen, Germany) and Sysmex Corporation (Kobe, Japan) have renewed their long-standing global supply, distributorship, sales and service agreement for a broad portfolio of hemostasis... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.